Rocatinlimab exhibits positive results in phase 3 study for atopic dermatitis

Key takeaways:

• Rocatinlimab is an investigational therapy that targets inflammation in atopic dermatitis.
• A phase 3 study showed rocatinlimab is beneficial in clearing signs and symptoms of disease.

Rocatinlimab exhibited promising results in the phase 3 ROCKET HORIZON trial for the treatment of moderate to severe atopic dermatitis, Kyowa Kirin announced in a press release.

Rocatinlimab is an investigational therapy that targets the OX40 receptor, a key driver in systemic and local inflammation in AD. The randomized, placebo-controlled, double-blind phase 3 ROCKET HORIZON study evaluating rocatinlimab achieved its co-primary endpoints.

"We are very pleased to have achieved statistically significant efficacy results over placebo which are consistent for co-primary endpoints and all key secondary endpoints,” Takeyoshi Yamashita, PhD, senior managing executive officer and chief medical officer at Kyowa Kirin, said in the release. “We look forward to further demonstrating that rocatinlimab, a potential T-cell rebalancing therapy, may help patients with moderate to severe atopic dermatitis as a new therapeutic option.”

While the company plans to release full results at a later medical conference, the press release reports that HORIZON met its coprimary endpoints with 19.3% of rocatinlimab-treated patients achieving IGA-AD 0 or 1 and 32.8% achieving EASI 75 by week 24 compared with 6.6% and 13.7% of the placebo groups, respectively (P < .001 for both).

The rates of adverse events were also comparable to those found in previous phase 2b results.